Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial

Autor: Edet B, Bonilla-Escobar Fj, Creanga Aa, François Dabis, Claire Rekacewicz, Uduak Okomo, Collins Iwuji, Tiggelaar Sm, Charlton Bm, Anthony Nardone, Adelufosi A, Aquaisua E, Marie-Louise Newell, Esu E, Joanna Orne-Gliemann, Kuhlmann Aks, Ejemot-Nwadiaro R, Ellie J Ricketts, Frank Tanser, Zhao H, Jones Lf, Joseph Larmarange, Cam McNulty, Rodolphe Thiébaut, Town K, Wu E, Rugman C, Ogugbue M, Msiska Tw, Gullo S, Jiang T, Thomas Hartney, Kate Folkard, Bello S, M Chibuzor, Nonhlanhla Okesola, Ortega-Loubon C, Galavotti C, Donna M. Lecky, Borus J, Wu R, Ortega-Lenis D, Xu F, Rojas-Mirquez Jc, Iwara Arikpo, Martin M Meremikwu, Dachi Arikpo, Okoye I, Vargas G
Přispěvatelé: DARMIGNY, Sandrine, Research Department of Infection and Population Health [London], University College of London [London] (UCL), Africa Centre for Health and Population Studies, University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN)-Medical Research Council of South Africa, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPCité), University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Human Health and Development, University of Southampton, University of KwaZulu-Natal (UKZN)-Medical Research Council of South Africa, Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence nationale de recherches sur le sida et les hépatites virales, ANRS France Recherche Nord & sud Sida-hiv hépatites, Global Health Research Institute, Hopkins Marine Station [Stanford], Stanford University, University College of London [London] ( UCL ), University of KwaZulu-Natal ( UKZN ) -Medical Research Council of South Africa, Institut de Santé Publique, d'Epidémiologie et de Développement ( ISPED ), Centre population et développement ( CEPED - UMR_D 196 ), Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), ANRS, University of Southampton [Southampton], HOPKINS MARINE STATION, Stanford University [Stanford], 12249, The French National Agency for Aids and Viral Hepatitis Research (ANRS), 81151938, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, International Initiative for Impact Evaluation, Merck, Gilead Sciences, 097410/Z/11/Z, Wellcome Trust
Jazyk: angličtina
Rok vydání: 2016
Předmět:
RNA viruses
Questionnaires
Male
Rural Population
0301 basic medicine
Epidemiology
[SDV]Life Sciences [q-bio]
lcsh:Medicine
HIV Infections
Human sexuality
Pathology and Laboratory Medicine
Public opinion
Geographical locations
South Africa
0302 clinical medicine
Immunodeficiency Viruses
Health care
Medicine and Health Sciences
Medicine
Public and Occupational Health
030212 general & internal medicine
ComputingMilieux_MISCELLANEOUS
media_common
education.field_of_study
AIDS Serodiagnosis
virus diseases
HIV diagnosis and management
[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie
General Medicine
Continuity of Patient Care
Middle Aged
Vaccination and Immunization
3. Good health
Abortion law
[SDV] Life Sciences [q-bio]
Sexual Partners
Medical Microbiology
Research Design
HIV epidemiology
Viral Pathogens
Viruses
Cluster Trials
Female
Health education
Pathogens
Attitude to Health
Research Article
Adult
Drug Research and Development
Anti-HIV Agents
media_common.quotation_subject
Immunology
HIV prevention
Population
Antiretroviral Therapy
Research and Analysis Methods
Microbiology
Young Adult
03 medical and health sciences
Antiviral Therapy
Nursing
Retroviruses
Humans
Clinical Trials
education
Microbial Pathogens
Conscience
Pharmacology
Survey Research
[ SDV ] Life Sciences [q-bio]
business.industry
Lentivirus
lcsh:R
Organisms
Biology and Life Sciences
HIV
030112 virology
Mental health
Diagnostic medicine
Self Care
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Law
Africa
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Preventive Medicine
Clinical Medicine
People and places
business
Zdroj: PLoS Medicine, Vol 13, Iss 8, p e1002107 (2016)
PLoS Medicine
PLoS Medicine, 2016, 13 (8), ⟨10.1371/journal.pmed.1002107⟩
PLoS Medicine, Public Library of Science, 2016, 13 (8)
BASE-Bielefeld Academic Search Engine
HAL
ISSN: 1549-1676
1549-1277
DOI: 10.1371/journal.pmed.1002107⟩
Popis: Background The 2015 WHO recommendation of antiretroviral therapy (ART) for all immediately following HIV diagnosis is partially based on the anticipated impact on HIV incidence in the surrounding population. We investigated this approach in a cluster-randomised trial in a high HIV prevalence setting in rural KwaZulu-Natal. We present findings from the first phase of the trial and report on uptake of home-based HIV testing, linkage to care, uptake of ART, and community attitudes about ART. Methods and Findings Between 9 March 2012 and 22 May 2014, five clusters in the intervention arm (immediate ART offered to all HIV-positive adults) and five clusters in the control arm (ART offered according to national guidelines, i.e., CD4 count ≤ 350 cells/μl) contributed to the first phase of the trial. Households were visited every 6 mo. Following informed consent and administration of a study questionnaire, each resident adult (≥16 y) was asked for a finger-prick blood sample, which was used to estimate HIV prevalence, and offered a rapid HIV test using a serial HIV testing algorithm. All HIV-positive adults were referred to the trial clinic in their cluster. Those not linked to care 3 mo after identification were contacted by a linkage-to-care team. Study procedures were not blinded. In all, 12,894 adults were registered as eligible for participation (5,790 in intervention arm; 7,104 in control arm), of whom 9,927 (77.0%) were contacted at least once during household visits. HIV status was ever ascertained for a total of 8,233/9,927 (82.9%), including 2,569 ascertained as HIV-positive (942 tested HIV-positive and 1,627 reported a known HIV-positive status). Of the 1,177 HIV-positive individuals not previously in care and followed for at least 6 mo in the trial, 559 (47.5%) visited their cluster trial clinic within 6 mo. In the intervention arm, 89% (194/218) initiated ART within 3 mo of their first clinic visit. In the control arm, 42.3% (83/196) had a CD4 count ≤ 350 cells/μl at first visit, of whom 92.8% initiated ART within 3 mo. Regarding attitudes about ART, 93% (8,802/9,460) of participants agreed with the statement that they would want to start ART as soon as possible if HIV-positive. Estimated baseline HIV prevalence was 30.5% (2,028/6,656) (95% CI 25.0%, 37.0%). HIV prevalence, uptake of home-based HIV testing, linkage to care within 6 mo, and initiation of ART within 3 mo in those with CD4 count ≤ 350 cells/μl did not differ significantly between the intervention and control clusters. Selection bias related to noncontact could not be entirely excluded. Conclusions Home-based HIV testing was well received in this rural population, although men were less easily contactable at home; immediate ART was acceptable, with good viral suppression and retention. However, only about half of HIV-positive people accessed care within 6 mo of being identified, with nearly two-thirds accessing care by 12 mo. The observed delay in linkage to care would limit the individual and public health ART benefits of universal testing and treatment in this population. Trial registration ClinicalTrials.gov NCT01509508
Collins Iwuji and colleagues report implementation indicators and early health outcomes from the first phase of a cluster-randomized trial of immediate antiretroviral therapy to all HIV-positive individuals in rural KwaZulu-Natal, South Africa.
Author Summary Why Was This Study Done? A study in stable sexual partners in which one partner was HIV-positive and the other partner was HIV-negative (and both partners had disclosed to each other) showed that if the HIV-positive partner was on antiretroviral therapy, there was a 96% reduction in HIV transmission from the HIV-positive partner to the HIV-negative partner. However, we do not know if antiretroviral therapy prescribed to HIV-positive individuals in the general population—and where individuals might not disclose their HIV status to sexual partners—would have a similar impact on HIV transmission. It is important to determine whether prescribing antiretroviral therapy to all HIV-positive individuals is more effective at decreasing HIV transmission than starting individuals on antiretroviral therapy only once their HIV has progressed to the point at which local HIV treatment guidelines currently recommend that HIV-positive individuals start treatment. What Did the Researchers Do and Find? We designed an experiment to investigate whether antiretroviral therapy can reduce new HIV infections in the general population, and piloted the trial in ten communities in KwaZulu-Natal, South Africa, to check whether starting HIV-positive individuals on antiretroviral therapy directly after diagnosis is feasible and acceptable. We visited people in their homes, offered HIV rapid tests every six months to all individuals 16 years and older, and referred identified HIV-positive individuals to trial clinics, where they were offered antiretroviral therapy either regardless of their CD4 count (intervention group) or when they were treatment-eligible per current national guidelines (control group). During the two-year study, we contacted 9,927 (77%) of 12,894 eligible individuals and ascertained the HIV status of 80% of contacted women and 75% of contacted men. HIV-positive status was ascertained for 1,339 adults who were not previously in care; 1,177 were followed in the trial at least 6 mo after referral, of whom 559 (47.5%) engaged with care within this period. What Do These Findings Mean? Our findings show good acceptance of home-based HIV testing in rural South Africa but highlight the challenges in reaching adequate numbers of people to offer HIV tests to, especially among men. We also found that linkage to care was slower than expected, but amongst those who reached the clinics, uptake of antiretroviral therapy was high, with the majority of individuals achieving good control of the virus. Our study informs health care professionals, planners, and policy makers about the challenges that need to be addressed to achieve the UNAIDS target of 90% of people living with HIV aware of their HIV diagnosis, 90% on antiretroviral therapy, and 90% achieving good control of the virus, with testing and treatment offered to all.
Databáze: OpenAIRE
Externí odkaz: